Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial

Published:2020-05-01 Issue:5 Volume:27 Page:471-484
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Koba Shinji¹,Inoue Ikuo²,Cyrille Marcoli³,Lu Chen³,Inomata Hyoe⁴,Shimauchi Junichiro⁴,Kajinami Kouji⁵

Affiliation:

1. Department of Medicine, Division of Cardiology, Showa University School of Medicine

2. Department of Endocrinology and Diabetes, Saitama Medical University

3. Amgen Inc., Thousand Oaks

4. Amgen Astellas BioPharma K.K.

5. Department of Cardiology, Kanazawa Medical University

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/27/5/27_50963/_pdf

Reference17 articles.

1. 1) Bruckert E, Hayem G, Dejager S, Yau C and Bégaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther, 2005; 19: 403-414

2. 2) Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y and Kajinami K: Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J, 2018; 82: 1008-1016

3. 3) Riaz H, Khan AR, Khan MS, Rehman KA, Alansari SAR, Gheyath B, Raza S, Barakat A, Luni FK, Ahmed H and Krasuski RA: Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol, 2017; 120: 774-781

4. 4) Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN and Chilcott J: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med, 2009; 265: 568-580

5. 5) Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM and Stein EA: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA, 2012; 308: 2497-2506

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study;BMC Medical Research Methodology;2024-06-22

2. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease;Pharmacoepidemiology;2024-03-05

3. Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan;Circulation Journal;2024-03-01

4. The Link between miRNAs and PCKS9 in Atherosclerosis;Current Medicinal Chemistry;2023-11-16

5. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease;Current Pharmaceutical Design;2023-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3